Published in Oncologist on January 27, 2011
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol (1996) 3.63
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2007) 1.69
Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol (1996) 1.65
Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol (2010) 1.64
Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol (2005) 1.62
Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol (2003) 1.47
Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. Int J Gynecol Pathol (2003) 1.35
Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol (2002) 1.24
Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol (2002) 1.23
Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand (1971) 1.21
Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol (1999) 1.09
Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol (2001) 1.08
Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol (2002) 1.03
Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Acta Obstet Gynecol Scand (2008) 0.91
Proliferative serous tumors of the ovary. Histologic features and prognosis. Am J Surg Pathol (1978) 0.91
Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary. Oncologist (2011) 0.90
Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol (2005) 0.89
A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component. Am J Surg Pathol (2002) 0.85
Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol (2010) 0.85
Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med (2014) 4.01
Incidence of venous thromboembolism after minimally invasive surgery in patients with newly diagnosed endometrial cancer. Obstet Gynecol (2012) 2.09
Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol (2012) 1.67
Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol (2009) 1.62
The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer (2011) 1.60
The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol (2012) 1.52
Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. Gynecol Oncol (2012) 1.47
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol (2012) 1.46
Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol (2010) 1.42
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol (2010) 1.37
The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol (2009) 1.33
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol (2009) 1.27
Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One (2010) 1.25
Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecol Oncol (2008) 1.20
Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol (2008) 1.16
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol (2009) 1.14
Comparison of robotic and laparoscopic hysterectomy for benign gynecologic disease. Obstet Gynecol (2014) 1.12
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol (2009) 1.11
A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer (2011) 1.06
Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol (2006) 1.01
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer (2014) 1.01
High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol (2012) 0.98
A prospective study of the feasibility and acceptability of a Web-based, electronic patient-reported outcome system in assessing patient recovery after major gynecologic cancer surgery. Gynecol Oncol (2012) 0.97
The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol Oncol (2011) 0.96
A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist (2009) 0.96
Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol (2009) 0.95
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 0.94
External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecol Oncol (2012) 0.90
Prognostic value of lymph node ratio and clinicopathologic parameters in patients diagnosed with stage IIIC endometrial cancer. Obstet Gynecol (2012) 0.90
p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol (2009) 0.90
Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol (2009) 0.88
Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. Gynecol Oncol (2013) 0.87
Advances in the management of endometrial carcinoma. Gynecol Oncol (2011) 0.87
Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol (2005) 0.87
Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters. Int J Gynecol Cancer (2013) 0.86
Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology (2013) 0.85
Electrocautery-associated vascular injury during robotic-assisted surgery. Obstet Gynecol (2012) 0.84
Pelvic insufficiency fractures in patients with cervical and endometrial cancer treated with postoperative pelvic radiation. Gynecol Oncol (2012) 0.83
Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol (2013) 0.81
Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol (2008) 0.81
Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. Gynecol Oncol (2011) 0.79
Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal. Am J Surg Pathol (2013) 0.78
Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity. Gynecol Oncol (2013) 0.77
Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol (2012) 0.77
Potential pitfalls of the rapid uptake of new technology in surgery: can comparative effectiveness research help? J Clin Oncol (2012) 0.77
Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment. Int J Gynecol Cancer (2013) 0.76
Tumoral displacement into fallopian tubes in patients undergoing robotically assisted hysterectomy for newly diagnosed endometrial cancer. Int J Gynecol Pathol (2013) 0.76
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer (2016) 0.75
A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer. Int J Gynecol Cancer (2017) 0.75
In reply. Obstet Gynecol (2013) 0.75
Optimal study design and the CONSORT guidelines. Fertil Steril (2005) 0.75
Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin. Int J Gynecol Pathol (2016) 0.75
Improving safety in robotic surgery: intraoperative crisis checklist. J Surg Oncol (2013) 0.75
Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol (2012) 0.75
The highs and lows of targeted therapies. Oncology (Williston Park) (2015) 0.75
Radical Trachelectomy for the Treatment of Early-Stage Cervical Cancer: A Systematic Review. Obstet Gynecol (2020) 0.75
Grading uterine endometrioid carcinoma: a proposal that binary is best. Am J Surg Pathol (2014) 0.75